Future Market Insights (FMI) projects the global probiotic supplements market to expand from USD 14.6 billion in 2026 to USD ...

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using ...

Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash ...

Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY). Cash (AUD $10.0 million ...

Planning to fast during Ramadan with IBS? Know the risks, warning symptoms to watch for, safe diet tips, and when skipping ...

Khaberni - Irritable bowel syndrome is one of the most common digestive system disorders, characterized by bloating, abdominal pain, cramps, and changes in bowel patterns ranging from constipation.

Khaberni - Patients with irritable bowel syndrome face special challenges during the holy month of Ramadan due to changes in ...

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs fo ...

XPHOZAH® (tenapanor) finishes 2025 with $103.6 million in revenue Revenue for XPHOZAH in 2025 was $103.6 million reflecting year-over-year growth in total XPHOZAH dispenses, including an increased ...

By bringing gravity into the equation, we can focus on effective strategies for managing IBS in space and on Earth.